Product Overview

GenBioPro’s initial focus is to commercialize low cost and fast-to-market oncology supportive therapies as "super-generic" products such as the fentanyl-transdermal patch, alendronate as an oral bisphosphonate, ondansetron-nasal spray fro treating chemotherpay -induced nausea & vomiting, octreotide-SDI for intractable diarrhea from chemotherapy, and "needle-free" recombinant human growth hormone for AIDS- and cancer-related wasting. These are products that can be sold in markets where the Company can obtain regulatory approval and begin selling within 3-6 months. These well-understood generic products will be registered and sold in the countries of Latin America, Africa, Asia, India, and Eastern Europe including Russia, while being further developed for approvals in U.S., Canada, and in the European Union. After the first wave of Oncology Supportive Care therapeutics hit the markets as "super-generics", revenues from sales and partnerships/distributorships will be used to commercialize additional "super-generics" and "super-biosimilars" such as "needle-free" insulin, growth hormone, Factor VIII, G-CSF and erythropoietin.